{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T14:40:46Z","timestamp":1731336046519,"version":"3.28.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,11]]},"DOI":"10.7759\/cureus.73434","type":"journal-article","created":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T14:07:16Z","timestamp":1731334036000},"source":"Crossref","is-referenced-by-count":0,"title":["Durable Response to Combined Nivolumab, Lenvatinib, and Radiation Therapy Against Oligometastatic Hepatocellular Carcinoma"],"prefix":"10.7759","author":[{"given":"Sewoon","family":"Chun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin M","family":"Coyne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won Jin","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.601710","article-title":"Etiology of hepatocellular carcinoma: special focus on fatty liver disease","volume":"10","author":"Suresh D","year":"2020","unstructured":"Suresh D, Srinivas AN, Kumar DP. Etiology of hepatocellular carcinoma: special focus on fatty liver disease. Front Oncol. 2020, 10:601710. 10.3389\/fonc.2020.601710","journal-title":"Front Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray F","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018, 68:394-424. 10.3322\/caac.21492","journal-title":"CA Cancer J Clin"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.4103\/jrms.JRMS_1017_18","article-title":"Predictors of 5 year survival rate in hepatocellular carcinoma patients","volume":"24","author":"Sarveazad A","year":"2019","unstructured":"Sarveazad A, Agah S, Babahajian A, Amini N, Bahardoust M. Predictors of 5 year survival rate in hepatocellular carcinoma patients. J Res Med Sci. 2019, 24:86. 10.4103\/jrms.JRMS_1017_18","journal-title":"J Res Med Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn RS","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, et al.. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020, 382:1894-905. 10.1056\/NEJMoa1915745","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.01.072","article-title":"A phase 2 clinical trial of SABR followed by immediate vertebroplasty for spine metastases","volume":"104","author":"Wardak Z","year":"2019","unstructured":"Wardak Z, Bland R, Ahn C, et al.. A phase 2 clinical trial of SABR followed by immediate vertebroplasty for spine metastases. Int J Radiat Oncol Biol Phys. 2019, 104:83-9. 10.1016\/j.ijrobp.2019.01.072","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1148\/rg.220084","article-title":"Imaging features in the liver after stereotactic body radiation therapy","volume":"42","author":"Navin PJ","year":"2022","unstructured":"Navin PJ, Olson MC, Mendiratta-Lala M, Hallemeier CL, Torbenson MS, Venkatesh SK. Imaging features in the liver after stereotactic body radiation therapy. Radiographics. 2022, 42:2131-48. 10.1148\/rg.220084","journal-title":"Radiographics"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr4902","article-title":"Prognostic scores and survival rates by etiology of hepatocellular carcinoma: a review","volume":"15","author":"Calderon-Martinez E","year":"2023","unstructured":"Calderon-Martinez E, Landazuri-Navas S, Vilchez E, et al.. Prognostic scores and survival rates by etiology of hepatocellular carcinoma: a review. J Clin Med Res. 2023, 15:200-7. 10.14740\/jocmr4902","journal-title":"J Clin Med Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v29.i10.1551","article-title":"Systemic treatment for unresectable hepatocellular carcinoma","volume":"29","author":"Leowattana W","year":"2023","unstructured":"Leowattana W, Leowattana T, Leowattana P. Systemic treatment for unresectable hepatocellular carcinoma. World J Gastroenterol. 2023, 29:1551-68. 10.3748\/wjg.v29.i10.1551","journal-title":"World J Gastroenterol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24300","article-title":"Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma receiving external beam radiotherapy","volume":"115","author":"He J","year":"2009","unstructured":"He J, Zeng ZC, Tang ZY, et al.. Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma receiving external beam radiotherapy. Cancer. 2009, 115:2710-20. 10.1002\/cncr.24300","journal-title":"Cancer"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3857\/roj.2019.00136","article-title":"Prognostic factors in hepatocellular carcinoma patients with bone metastases","volume":"37","author":"Kim S","year":"2019","unstructured":"Kim S, Choi Y, Kwak DW, Lee HS, Hur WJ, Baek YH, Lee SW. Prognostic factors in hepatocellular carcinoma patients with bone metastases. Radiat Oncol J. 2019, 37:207-14. 10.3857\/roj.2019.00136","journal-title":"Radiat Oncol J"},{"key":"ref11","article-title":"LBA34 primary results from the phase III LEAP-002 study: lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)","volume":"33","author":"Finn RS","year":"2022","unstructured":"Finn RS, Kudo M, Merle P, et al.. LBA34 primary results from the phase III LEAP-002 study: lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC). Ann Oncol. 2022, 33:S1401.","journal-title":"Ann Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal AG","year":"2023","unstructured":"Singal AG, Llovet JM, Yarchoan M, et al.. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023, 78:1922-65. 10.1097\/HEP.0000000000000466","journal-title":"Hepatology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01102-y","article-title":"Radiotherapy combined with immunotherapy: the dawn of cancer treatment","volume":"7","author":"Zhang Z","year":"2022","unstructured":"Zhang Z, Liu X, Chen D, Yu J. Radiotherapy combined with immunotherapy: the dawn of cancer treatment. Signal Transduct Target Ther. 2022, 7:258. 10.1038\/s41392-022-01102-y","journal-title":"Signal Transduct Target Ther"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.30","article-title":"Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?","volume":"13","author":"Bernstein MB","year":"2016","unstructured":"Bernstein MB, Krishnan S, Hodge JW, Chang JY. Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?. Nat Rev Clin Oncol. 2016, 13:516-24. 10.1038\/nrclinonc.2016.30","journal-title":"Nat Rev Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2023.07.001","article-title":"Radiation therapy with combination therapy of immune checkpoint inhibitors and antiangiogenic therapy for hepatocellular carcinoma","volume":"118","author":"Ning C","year":"2024","unstructured":"Ning C, Zhang X, Wang Y, et al.. Radiation therapy with combination therapy of immune checkpoint inhibitors and antiangiogenic therapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2024, 118:1461-71. 10.1016\/j.ijrobp.2023.07.001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01157","article-title":"Combined stereotactic body radiotherapy and checkpoint inhibition in unresectable hepatocellular carcinoma: a potential synergistic treatment strategy","volume":"9","author":"Chiang CL","year":"2019","unstructured":"Chiang CL, Chan AC, Chiu KW, Kong FS. Combined stereotactic body radiotherapy and checkpoint inhibition in unresectable hepatocellular carcinoma: a potential synergistic treatment strategy. Front Oncol. 2019, 9:1157. 10.3389\/fonc.2019.01157","journal-title":"Front Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1289434","article-title":"Consolidative thoracic radiation therapy for extensive-stage small cell lung cancer in the era of first-line chemoimmunotherapy: preclinical data and a retrospective study in Southern Italy","volume":"14","author":"Longo V","year":"2023","unstructured":"Longo V, Della Corte CM, Russo A, et al.. Consolidative thoracic radiation therapy for extensive-stage small cell lung cancer in the era of first-line chemoimmunotherapy: preclinical data and a retrospective study in Southern Italy. Front Immunol. 2023, 14:1289434. 10.3389\/fimmu.2023.1289434","journal-title":"Front Immunol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.03.002","article-title":"Use of radiation therapy among patients with extensive-stage small-cell lung cancer receiving immunotherapy: Canadian consensus recommendations","volume":"179","author":"Sun A","year":"2023","unstructured":"Sun A, Abdulkarim B, Blais N, et al.. Use of radiation therapy among patients with extensive-stage small-cell lung cancer receiving immunotherapy: Canadian consensus recommendations. Lung Cancer. 2023, 179:107166. 10.1016\/j.lungcan.2023.03.002","journal-title":"Lung Cancer"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-21-682","article-title":"Combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer","volume":"10","author":"Wang Z","year":"2021","unstructured":"Wang Z, Wei L, Li J, et al.. Combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer. Transl Lung Cancer Res. 2021, 10:4368-79. 10.21037\/tlcr-21-682","journal-title":"Transl Lung Cancer Res"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10102481","article-title":"Oligoprogression of solid tumors on immune checkpoint inhibitors: the impact of local ablative radiation therapy","volume":"10","author":"Sindhu KK","year":"2022","unstructured":"Sindhu KK, Nehlsen AD, Lehrer EJ, Rowley JP, Stock RG, Galsky MD, Buckstein M. Oligoprogression of solid tumors on immune checkpoint inhibitors: the impact of local ablative radiation therapy. Biomedicines. 2022, 10:2481. 10.3390\/biomedicines10102481","journal-title":"Biomedicines"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/243224-durable-response-to-combined-nivolumab-lenvatinib-and-radiation-therapy-against-oligometastatic-hepatocellular-carcinoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T14:07:17Z","timestamp":1731334037000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/243224-durable-response-to-combined-nivolumab-lenvatinib-and-radiation-therapy-against-oligometastatic-hepatocellular-carcinoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,11]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.73434","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,11]]}}}